Guardant Health stock surges on colon cancer blood test news
Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intact. The new price target came less than a day after a ...
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- GHGuardant Health Up
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
